Business Context and Reporting Period
Company: Travere Therapeutics, Inc. (TVTX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 15, 2025
Event: The U.S. Food and Drug Administration (FDA) accepted the Company's supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS).
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a regulatory event and does not contain financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Data
The filing details the regulatory status of FILSPARI for FSGS, supported by the following clinical data:
- Phase 3 DUPLEX Study: Achieved the pre-specified interim endpoint for FSGS partial remission of proteinuria (FPRE) at 36 weeks with statistical significance. While the primary efficacy eGFR slope endpoint over 108 weeks was not achieved, two-year results showed clinically meaningful benefit, including significant proteinuria reduction, higher remission rates, and a lower rate of end-stage kidney disease compared to active control.
- Phase 2 DUET Study: Met the primary efficacy endpoint for the combined treatment group, demonstrating greater than a two-fold reduction in proteinuria compared to irbesartan.
- Safety Profile: Sparsentan was well-tolerated with a safety profile consistent across trials and comparable to the active control (irbesartan), with no drug-induced liver injury or fluid overload reported.
Guidance, Outlook, and Risks
Regulatory Timeline: The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 13, 2026. An advisory committee meeting is currently planned to discuss the application.
Market Potential: If approved, FILSPARI could become the first and only FDA-approved medicine for FSGS, a rare kidney condition affecting an estimated 40,000 patients in the U.S.
Risks and Uncertainties:
- No guarantee that the FDA will grant approval for FILSPARI in FSGS on the anticipated timeline or at all.
- Risks related to the ongoing commercial launch of FILSPARI in IgAN.
- Macroeconomic conditions, including potential funding constraints and supply chain disruptions.
- Regulatory risks associated with the new administration, including potential changes in FDA staffing, prioritization, and tariffs.
- Competitive risks and uncertainties regarding market acceptance, pricing, and reimbursement.
Investor Verification Checklist
- Verify the final outcome of the FDA advisory committee meeting regarding the FILSPARI sNDA for FSGS.
- Monitor the PDUFA target action date of January 13, 2026, for any potential delays or extensions.
- Review the Company's most recent Form 10-K or 10-Q for current cash runway and liquidity status, as this 8-K does not provide financial data.
- Assess the impact of the ongoing commercial launch of FILSPARI for IgAN on the Company's overall financial performance.
- Confirm the size of the addressable patient population for FSGS and potential reimbursement hurdles.